OBJECTIVES: Balloon sinuplasty (BSP) is a novel technology to treat patients with chronic rhinosinusitis (CRS) refractory to conservative care. The BSP technology is an alternative tool used during functional endoscopic sinus surgery (FESS). Recent clinical trials have identified favorable clinical outcomes of BSP compared to classic FESS. Specifically, the non-invasiveness of the procedure may result in fewer post-operative treatments and complications. These findings point to potential cost effectiveness of the BSP procedure versus classic FESS. In this study, the cost of treatment for patients undergoing either classic FESS or BSP was compared using a budget impact model. The model was designed to be versatile and allow for country-specific analyses using regional cost and care assumptions. METHODS: The budget impact model was designed to identify costs by therapeutic treatment (FESS vs. BSP vs. conservative care). Inputs included frequency and unit costs of preoperative work-ups (such as office visits and diagnostic procedures), index in- or out-patient surgery, frequency and unit cost of treatment for post-operative complications, post-operative procedures and relapse/reoperation rates. Secondary analyses included productivity calculations using a human capital approach. The follow-up period was limited to 2 years post-index. Supplementary analyses were conducted to determine the cost impact of early intervention on total budget. RESULTS: At 1 and 2-year post-operative time points and using assumptions specific to different European countries, the cost of BSP was lower in specific target groups than that of FESS. CONCLUSIONS: The model suggests savings in target groups, based on clinical outcomes data from BSP and classic FESS, at 2 years post-operative. The patient friendly technology offers to payers the opportunity to seek efficient resource utilization whilst diminishing costs.